Trial ID
21308
Sponsor ID
Zentalis Pharmaceuticals
A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN‑c3 in Combination with Niraparib in Subjects with Platinum-Resistant Ovarian Cancer
Principal Investigator
Alexander I. Spira, MD, PhD, FACP
1 Location
Locations
Fairfax Office
Learn More About This Trial
Other Relevant Trials
Trial ID
DK210 (EGFR)
Sponsor ID
DEKA Biosciences
Dose-finding Phase 1 Trial: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Inoperable Locally Advanced and/or Metastatic EGFR+ Tumors With Progressive Disease Failing Systemic Therapy
Principal Investigator
Alexander I. Spira, MD, PhD, FACP
Trial ID
21457
Sponsor ID
Artistry-7
(ALKS 4230-007/GOG-3063) A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)
Principal Investigator
Robert L. Marsh, MD
5 Locations
